Tandutinib

Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) [1][2]. Tandutinib has the ability to cross the blood-brain barrier[3].

Product Specifications

CAS Number

[387867-13-2]

Product Name Alternative

MLN518; CT53518

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; c-Kit; FLT3; PDGFR

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tandutinib.html

Purity

99.48

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2=C(C(C=C3OCCCN4CCCCC4)=NC=N2)C=C3OC)CC1)NC5=CC=C(OC(C)C)C=C5

Molecular Formula

C31H42N6O4

Molecular Weight

562.70

Precautions

H302, H315, H319, H335

References & Citations

[1]Kelly LM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) . Cancer Cell, 2002, 1 (5), 421-432.|[2]Griswold IJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood, 2004, 104 (9), 2912-2918.|[3]Yang JJ, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010 Dec;4 (4) :201-12.